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Carboplatin is a second-generation platinum compound which was
developed in an attempt to overcome side-effects such as renal
damage, peripheral neuropathy and ototoxicity, which were
associated with its parent compound cisplatin. It is now a first-line
drug for several paediatric tumours including germ cell tumours
(Pinkerton et al, 1990), primitive neuroectodermal tumours and
low-grade gliomas (Lashford et al, 1996), neuroblastoma (Castel
et al, 1995) and malignant mesenchymal tumours (Doz and
Pinkerton, 1994), and has demonstrated activity in other malig-
nancies including Wilm’s tumour (de Camargo et al, 1994;
Ettinger et al, 1994).
Initial reports of the effect of carboplatin on renal function in
children indicated little or no impairment in glomerular filtration
following carboplatin (Castello et al, 1990; Pinkerton et al, 1990;
Stevens et al, 1991; Brandt and Broadbent, 1993), even when
doses of 1000 mg m–2 course–1 were used (Castello et al, 1990).
Hypomagnesaemia has been reported after carboplatin in children
(Skinner et al, 1991a; Ettinger et al, 1994). There has been one
case report of acute renal failure following high-dose carboplatin
in a child (Frenkel et al, 1995).
The purpose of this investigation was to examine renal function
in a cohort of children who had completed treatment with carbo-
platin, to determine whether renal function changed over time after
treatment, and to identify possible risk factors for nephrotoxicity.
MATERIALS AND METHODS
Patients
Twenty-three patients (ten female) were studied. All had received
carboplatin but not cisplatin or ifosfamide at the Children’s
Cancer Unit, Newcastle upon Tyne between 1988 and November
1994. Their median age at diagnosis was 4.6 years (range 0.4–
15.4 years). The carboplatin dose (mg m–2) along with concurrent
heights, weights and GFR measured by 51Cr–EDTA clearance,
together with details of any treatment with nephrotoxic antibiotics
or chemotherapy, were recorded. In 11 children 51Cr–EDTA
clearances were performed at least once every second course
of chemotherapy which enabled the cumulative area under the
plasma concentration versus time curve (AUC) of carboplatin for
all courses to be calculated. Carboplatin AUC was calculated
according to the paediatric dosing equation (Newell et al, 1993):
AUC [mg/ml.min] = Dose [mg] / (GFR [ml/min] +
(0.36 ´ BW [kg])) where BW equals the body weight.
Patients were treated on a variety of different protocols. Three
received treatment with high-dose methotrexate, but no other
nephrotoxic anticancer agents were employed. Four children
received treatment with aminoglycoside antibiotics and four
received amphotericin B during supportive care after
chemotherapy. The case records of one child were not available,
but it is known that she did not receive any nephrotoxic
chemotherapy other than carboplatin. The median cumulative dose
(CD) of carboplatin was 2590 mg m–2 (range 1364–7133 mg m–2).
Patient characteristics and details of carboplatin doses adminis-
tered are summarized in Table 1.
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Methods
Investigation of renal function
We have previously described a protocol for the detailed
evaluation of glomerular, proximal and distal renal tubular
function (Skinner et al, 1991b). Glomerular filtration rate (GFR)
was measured from 51Cr-EDTA plasma clearance. A GFR < 90 ml
min–1 1.73 m–2 was considered to be below normal. Corresponding
plasma and urine specimens are obtained and serum magnesium
(S Mg), fractional excretion of magnesium (FEMg), serum ionized
calcium (S Ion Ca), fractional excretion of glucose (FEgluc), and
the ratios of the urine protein (Uprot:C), retinol binding protein
(URBP:C), lactate dehydrogenase (ULDH:C), alanine amino
peptidase (UAAP:C), alkaline phosphatase (UAKP:C) and
N-acetyl glucosaminidase (UNAG:C) to urine creatinine were
measured. Renal function was assessed 1 month, 6 months (1994
onwards), 1 year (1993 onwards) and 2 years after the completion
of treatment using this protocol. Before the first course of treat-
ment with carboplatin twenty-one children had GFR measured,
but only nine had a full assessment of renal function performed.
Change in renal function over time
GFR, S Mg, FEMg, S Ion Ca, FEgluc, Uprot:C, URBP:C,
ULDH:C, UAAP:C, UAKP:C and UNAG:C were evaluated by
paired Student’s t-test comparing before to completion of treat-
ment, and before to the regular time points after treatment.
Table 1 Characteristics of patients studied
Mean
Total Dose carboplatin
Age dose of intensity of dose each Other
Patient (years) Sex Diagnosis carboplatin carboplatin course nephrotoxic
Investigations (mg m–2) (mg m–2) (mg m–2) treatment
week–1)
1 15.1 M Glioma 4 y 7133 124 594
2 1.8 F Glioma 1 m 5239 135 524
3 13.1 F Dysgerminoma 1 m, 2 y 4063 180 677 AG
4 0.6 M Astrocytoma 6 m, 2 y 1364 196 742 AG
5 5.6 F PNET 1 m, 2 y 2294 167 1148 AG, Ampho
6 3.8 F PNET 1 m 2324 171 1162
7 4.6 M PNET 1 m 2365 197 1182
8 1.4 F Sacrococcygeal teratoma 1 m, 2 y NK NK NK NK
9 0.6 M Neuroblastoma 6 m, 1 y, 2 y 1364 222 682 AG
10 0.8 F Sacrococcygeal teratoma 1 m, 1 y, 2 y 3967 214 661
11 0.9 F Retinoblastoma 1 m, 2 y 1815 153 454
12 12.1 M Hypothalamic teratoma 1 m, 1 y 3855 156 550 Ampho,
MTX
13 12.3 F Hypothalamic teratoma P, 1 m, 1 y 2766 164 614 Ampho,
MTX
14 12.2 M PNET P, 1 m, 1 y 2389 199 1194
15 11.6 M Pineal teratoma P, 1 m, 6 m, 1 y 3560 106 508 Ampho,
MTX
16 4.7 M PNET P, 1 m, 1 y 2114 154 1056
17 1.2 M Low grade astrocytoma P, 1 m, 1 y 5485 141 499
18 15.4 M Hypothalamic teratoma P, 1 m, 6 m 6006 282 1001
19 1.4 M Teratoma 6 m, 2413 192 528
20 1.8 F Low-grade astrocytoma 6 m 7133 179 634
21 16.2 M Pineal dysgerminoma P, 1 m, 6 m 3801 166 603
22 10.9 F Low-grade astrocytoma P, 1 m, 6 m 2063 143 1032
23 0.4 M Teratoma P, 1 m 2222 171 555
Median 2590 169 648
Min 1364 106 454
Max 7133 282 1194
PNET = primitive neuroectodermal tumour. P = pretreatment, 1 m = 1 month, 6 m = 6 months, 1 y = 1 year, 2 y = 2 years, 4 y = 4 years. AG = aminoglycoside
antibiotics or vancomycin; Ampho = amphotericin; MTX = high dose methotrexate; NK = not known.
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Prediction of risk factors for carboplatin nephrotoxicity
Because there were significant changes in S Mg and GFR from
before to after completion of treatment they were chosen as indices
of carboplatin nephrotoxicity. As there was no significant change in
the values of S Mg and GFR over time after the completion of treat-
ment with carboplatin, the mean of all the post-treatment observa-
tions for S Mg and GFR for each patient, and the difference
between the pretreatment and the mean post-treatment result for
each patient were used as markers of carboplatin nephrotoxicity.
Pretreatment GFR, CD, DI, and AUC of carboplatin were
chosen as potential predictors of carboplatin nephrotoxicity. DI
was expressed as mg m–2 week–1 of carboplatin. Their importance
as predictors of nephrotoxicity was evaluated by linear regression
analysis.
These investigations were approved by the Joint Ethics
Committee of Newcastle Health Authority and the University of
Newcastle upon Tyne. Informed consent for participation was
obtained from the parents and, where appropriate, the patients.
RESULTS
Pretreatment renal function
Three patients had slightly low and three had slightly high GFRs
(79, 86 and 89, and 201, 207 and 217 ml min–1 1.73 m–2). All
results were confirmed as showing predicted volumes of distribu-
tion of 51Cr–EDTA within normal limits and as having good linear
fits on the clearance slope of the isotope. S Mg was normal in all
patients before treatment commenced.
Change in GFR and S Mg following carboplatin
S Mg (P = 0.0077) and GFR (P = 0.012) both fell significantly
during treatment with carboplatin. The mean reduction in S Mg
was 0.17 mmol l–1 (95% confidence interval (CI) 0.06–0.28), and
the mean fall in GFR was 22 ml min–1 1.73 m–2 (95% CI 5–38).
Figures 1 and 2 show the changes in S Mg and GFR from before to
up to 2 years after completion of treatment. GFR and S Mg did not
change significantly over the 2 years following the completion of
treatment. One patient had symptomatic hypomagnesaemia and
suffered a fit 1 year after completion of treatment when magne-
sium treatment was withdrawn. It was restarted and he has been
asymptomatic since then. No other patient had any clinically
important symptoms which could be attributed to renal damage.
Changes in other measures of renal function
Minor abnormalities of no clinical significance were noted for
S Ion Ca, FE Mg, FE gluc, Uprot:C, URBP:C, ULDH:C,
UAAP:C, UAKP:C, and UNAG:C after the completion of treat-
ment. There was a statistically significant but clinically unimpor-
tant fall in UNAG:C between 1 month after treatment and later
studies, mean fall 0.15 U mmol–1 creatinine (95% CI 0.03–0.27).
Prediction of risk factors for carboplatin nephrotoxicity
Increasing CD of carboplatin was inversely related to the mean S
Mg after treatment (P = 0.031, r2 0.212), and directly related to the
reduction in S Mg over the course of treatment (P < 0.001, r2 0.814)
(Figure 3). DI of carboplatin was not statistically related to S Mg
after treatment, or to change in S Mg from before to after treatment.
However, patient 18 with both a high CD (6006 mg m–2) and high DI
(282 mg m2 week–1) of carboplatin had the lowest mean S Mg after
treatment, whereas patients 1 and 20 had high CDs (7133 mg m–2
each) but low DIs (124 and 179 mg m–2 week–1) of carboplatin and
both had mean S Mg > 0.7 mmol l–1 after treatment, so increased DI
may be important with higher CDs of carboplatin. Cumulative AUC
of carboplatin was inversely related to mean S Mg after completion
of treatment (P = 0.004, r2 0.62) (Figure 4). This result is heavily
influenced by patient 18 who also had a high DI. There was insuffi-
cient data to compare cumulative AUC of carboplatin with change
in S Mg over the course of treatment. CD and cumulative AUC of
carboplatin were not related to GFR after the completion of treat-
ment, nor to change in GFR from before to after treatment.
Other risk factors for renal damage
Three patients with intracranial germ cell tumours received a
protocol which combined carboplatin with intermediate dose
methotrexate (1 g m–2) 10 days later. GFR in these children was 69,
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76 and 77ml min–1 1.73m–2 1 month after the completion of
therapy, but compared with patients receiving similar CDs of
carboplatin they did not have a disproportionate fall in GFR
following treatment. Each also received amphotericin B. Only one
other patient received amphotericin, and he had no recorded
nephrotoxicity. The number of patients receiving aminoglycoside
antibiotics was too small to permit statistical analysis, but there
was no obvious association with nephrotoxicity.
DISCUSSION
This study has shown that the predominant changes in renal func-
tion observed after treatment with carboplatin are reductions in
GFR and S Mg. The reduction in GFR is seen in spite of the fact
that there were five children under the age of 1 year. The change in
the surface area to weight ratio over the first year of life means that
when the GFR is expressed as a ratio to surface area it increases
over the first year of life (there are minimal changes in the second
year of life). There were insufficient younger patients to explore
this further, but this phenomenon may have reduced the magnitude
of the observed fall in GFR seen in this study. Qualitatively
similar, but quantitatively more severe, changes are also seen
after cisplatin treatment in children (Womer et al, 1985; Brock
et al, 1991). Higher CD of carboplatin was significantly correlated
with lower S Mg concentrations after treatment, as was higher
cumulative AUC of carboplatin. A statistical relationship between
DI of carboplatin and S Mg after treatment was not observed, but
this investigation does not have sufficient numbers to exclude an
effect at higher CDs and DIs of carboplatin.
Single doses of less than 800mg m–2 carboplatin have not been
found to be nephrotoxic in adults (Skillen et al, 1988; Mason et al,
1991), but renal damage has been documented with higher doses.
Adults with ovarian carcinoma treated with single agent carbo-
platin at a dose of 1000mg m–3 course–1 (median of 4 courses)
had a transient decrease in GFR during treatment which resolved
spontaneously after therapy was completed (Hardy et al, 1990). A
detailed study by Sleijfer et al also showed a 19% reduction in
GFR in adults with lung cancer receiving carboplatin at doses
of 400mg m–2 course–1 (maximum of five courses) (Sleijfer et al,
1989). Renal toxicity became the non-haemopoietic dose-limiting
toxicity when carboplatin was infused in doses of up to
2400mg m–2 as a single agent with haemopoietic stem cell rescue
(Shea et al, 1989), and in doses of up to 1600mg m–2 in combina-
tion with cyclophosphamide and etoposide (Shea et al, 1992). No
nephrotoxicity was seen when carboplatin to a total of 1500mg
m–2 was given along with high-dose etoposide to adults with germ
cell tumours (Nichols et al, 1992). There has also been a report of
interstitial nephritis associated with renal failure in two adults
with ovarian carcinoma who received intraperitoneal carboplatin
(McDonald et al, 1991), but these patients had been heavily
pretreated with cisplatin.
Brandt and Broadbent examined glomerular function in detail in
children receiving carboplatin using 51Cr–EDTA clearance (Brandt
and Broadbent, 1993). They found no significant difference
between initial GFR and GFR before the final course of treatment
in 26 children. However, the mean dose of carboplatin received by
their patients (2438mg m–2) was significantly less (P= 0.008,
unpaired Student’s t-test) than that given in this study
(3418mg m–2). In addition, no investigations were carried out after
the completion of treatment. Pinkerton et al reported no significant
nephrotoxicity in 21 patients receiving ‘JEB’ (Pinkerton et al,
1990). No patient had a GFR below 90ml min–1 1.73m–2 and
although falls in GFR of > 10% were noted in three patients there
was no overall significant difference between the pretreatment
GFR and the last GFR recorded during treatment in their patients.
They aimed to administer a carboplatin AUC of 5–6mg ml–1. min
based on GFR measured by 51Cr–EDTA clearance. The mean dose
received by their patients was around 2300mg m–2 with a
maximum of around 3250mg m–2. Stevens et al showed no signif-
icant change in GFR after treatment with carboplatin to a dose
of 1010mg m–2 in 19 patients and 2020mg m–2 in nine patients
(Stevens et al, 1991). Again, this is a significantly lower dose of
carboplatin than that received by the patients in the present study.
Frappaz et al reported one case of acute renal failure and a > 50%
reduction in GFR in six out of 39 patients receiving two courses
of carboplatin (800mg m–2/course) and etoposide for relapsed
neuroblastoma (Frappaz et al, 1992). These patients had received
prior nephrotoxic therapy (mean dose of cisplatin 409mg m–2).
Renal tubular damage resulting in hypomagnesaemia is a recog-
nized feature of cisplatin nephropathy in adults (Bitran et al, 1982;
Buckley et al, 1984; Flombaum, 1984; Hill and Russo, 1981; Salem
et al, 1984) and children (Brock et al, 1991). However, few
investigators have examined aspects of renal function other than
glomerular filtration in children who have received carboplatin.
Hypomagnesaemia has been previously reported in a subset of the
patients in this study (Skinner et al, 1991a). Other authors have
reported it as an infrequent problem during treatment in children
(Ettinger et al, 1994; Tscherning et al, 1994), and more frequently
in adults receiving high-dose carboplatin prior to autologous bone
marrow transplant (Shea et al, 1989). Goren et al reported chronic
sub-clinical renal tubular damage after carboplatin treatment
(Goren et al, 1987). Until now there have been no reports of chronic
hypomagnesaemia after carboplatin and the relationship between
CD of carboplatin and hypomagnesaemia has not been noted.
No change in GFR or S Mg has been demonstrated over time
after completion of treatment with carboplatin in the current study.
Little has been published on serial changes in renal function after
completion of treatment with carboplatin. Hardy et al showed a
significant reduction in median GFR from 80.5ml min–1 before
treatment to 66.0ml min–1 immediately after treatment in 28
0.9
0.8
0.7
0.6
0.5
M
e
a
n
 
S
 
M
g
 
p
o
s
t
-
t
r
e
a
t
m
e
n
t
10 20 30 40 50 60 70
Cumulative AUC of carboplatin
Figure 4Other risk factors for renal damageCumulative AUC of carboplatin and the mean serum magnesium
for each patient after treatmentpatients with ovarian carcinoma (dose 1 g m–2 course–1, median
four courses); however, there was a subsequent increase to 82 ml
min–1 at > 3 months post-treatment (Hardy et al, 1990).
Nephrotoxicity, as defined by a GFR < 90 ml min–1 1.73 m–2 or
a S Mg < 0.7 mmol l–1, could not be related to any pretreatment
measures of renal function in this study. Brandt and Broadbent did
not report more glomerular damage after treatment in children
with low GFRs prior to treatment with carboplatin (Brandt and
Broadbent, 1993).
Three patients were treated on a protocol that included high-
dose methotrexate. They all had low GFRs at completion of treat-
ment, but had also required treatment with amphotericin. There
was no obvious association between treatment with aminoglyco-
side antibiotics and nephrotoxicity. The use of amphotericin and
aminoglycoside antibiotics after high-dose carboplatin has been
reported to be associated with renal failure (Shea et al 1992;
Marina et al, 1993). Although there have been no reports of the
effect of combining carboplatin and high-dose methotrexate on
renal function, the combination of carboplatin and other poten-
tially nephrotoxic chemotherapy has been reported. High-dose
carboplatin and ifosfamide prior to autologous bone marrow
rescue has been associated with significant reductions in GFR,
especially at higher doses of carboplatin (Broun et al, 1991; Elias
et al, 1991; Wilson et al, 1992; Siegert et al, 1994), with less
damage reported in children. The combination of high-dose carbo-
platin, melphalan, vincristine and etoposide caused severe renal
toxicity when administered on the same day prior to autologous
bone marrow rescue (Gordon et al, 1992) rather than spread over
several days (Corbett et al, 1992).
In conclusion, treatment with carboplatin caused statistically
significant reductions in GFR and S Mg in this cohort of children
treated with carboplatin. However, only one patient had clinical
problems requiring magnesium supplementation. Renal function
was unchanged during the 2 years of observation following therapy.
Hypomagnesaemia following therapy with carboplatin occurs with
increasing frequency and severity after higher doses of carboplatin.
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